 Mark Dacey
Concepts (66)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Uveitis | 5 | 2024 | 148 | 1.320 |
Why?
| | Macular Edema | 3 | 2024 | 49 | 1.070 |
Why?
| | Dexamethasone | 2 | 2016 | 372 | 0.760 |
Why?
| | Visual Acuity | 4 | 2024 | 489 | 0.450 |
Why?
| | Phacoemulsification | 1 | 2016 | 122 | 0.420 |
Why?
| | Glucocorticoids | 2 | 2016 | 535 | 0.420 |
Why?
| | Cataract | 1 | 2016 | 238 | 0.390 |
Why?
| | Anti-Inflammatory Agents | 1 | 2014 | 474 | 0.320 |
Why?
| | Intravitreal Injections | 2 | 2016 | 71 | 0.220 |
Why?
| | Drug Implants | 2 | 2016 | 83 | 0.220 |
Why?
| | Triamcinolone Acetonide | 1 | 2024 | 20 | 0.220 |
Why?
| | Postoperative Complications | 1 | 2016 | 2919 | 0.200 |
Why?
| | Anterior Chamber | 1 | 2021 | 27 | 0.170 |
Why?
| | Panuveitis | 1 | 2021 | 8 | 0.170 |
Why?
| | Tomography, Optical Coherence | 3 | 2021 | 271 | 0.170 |
Why?
| | Pyridines | 1 | 2024 | 605 | 0.160 |
Why?
| | Drug Tolerance | 1 | 2017 | 100 | 0.130 |
Why?
| | Lens Implantation, Intraocular | 1 | 2016 | 80 | 0.110 |
Why?
| | Recurrence | 2 | 2016 | 1135 | 0.110 |
Why?
| | Uvea | 1 | 2013 | 4 | 0.100 |
Why?
| | Uveal Diseases | 1 | 2013 | 6 | 0.100 |
Why?
| | Uveomeningoencephalitic Syndrome | 1 | 2013 | 8 | 0.100 |
Why?
| | Lymphoproliferative Disorders | 1 | 2013 | 57 | 0.100 |
Why?
| | Vaccination | 1 | 2021 | 1423 | 0.090 |
Why?
| | Treatment Outcome | 4 | 2024 | 11679 | 0.090 |
Why?
| | Middle Aged | 7 | 2024 | 35875 | 0.090 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2017 | 985 | 0.080 |
Why?
| | Pemphigus | 1 | 2010 | 8 | 0.080 |
Why?
| | Conjunctival Diseases | 1 | 2010 | 23 | 0.080 |
Why?
| | Scleritis | 1 | 2010 | 28 | 0.080 |
Why?
| | Conjunctivitis | 1 | 2010 | 30 | 0.080 |
Why?
| | Adult | 6 | 2024 | 40449 | 0.080 |
Why?
| | Herpes Simplex | 1 | 2010 | 98 | 0.080 |
Why?
| | Aged | 4 | 2024 | 25913 | 0.080 |
Why?
| | Retrospective Studies | 3 | 2016 | 17066 | 0.070 |
Why?
| | Female | 7 | 2024 | 78271 | 0.060 |
Why?
| | Fundus Oculi | 2 | 2017 | 89 | 0.060 |
Why?
| | Male | 6 | 2024 | 72315 | 0.060 |
Why?
| | Aged, 80 and over | 2 | 2017 | 8265 | 0.060 |
Why?
| | Injections, Intraocular | 1 | 2024 | 14 | 0.050 |
Why?
| | Janus Kinase 1 | 1 | 2024 | 26 | 0.050 |
Why?
| | Fluorescein Angiography | 2 | 2017 | 189 | 0.050 |
Why?
| | Choroid | 1 | 2024 | 80 | 0.050 |
Why?
| | Triazoles | 1 | 2024 | 184 | 0.050 |
Why?
| | Humans | 8 | 2024 | 144759 | 0.040 |
Why?
| | Administration, Oral | 1 | 2024 | 847 | 0.040 |
Why?
| | Young Adult | 2 | 2017 | 14105 | 0.040 |
Why?
| | Double-Blind Method | 1 | 2024 | 2029 | 0.040 |
Why?
| | Adolescent | 2 | 2017 | 22428 | 0.030 |
Why?
| | Vitreous Body | 1 | 2017 | 117 | 0.030 |
Why?
| | Single-Blind Method | 1 | 2017 | 312 | 0.030 |
Why?
| | Infusions, Intravenous | 1 | 2017 | 423 | 0.030 |
Why?
| | Follow-Up Studies | 2 | 2017 | 5408 | 0.030 |
Why?
| | Physicians | 1 | 2024 | 939 | 0.030 |
Why?
| | Child | 1 | 2014 | 22633 | 0.030 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2017 | 2027 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 2024 | 6048 | 0.020 |
Why?
| | Valine | 1 | 2010 | 80 | 0.020 |
Why?
| | Acyclovir | 1 | 2010 | 96 | 0.020 |
Why?
| | Immunoglobulins, Intravenous | 1 | 2010 | 126 | 0.020 |
Why?
| | Medical Records | 1 | 2010 | 187 | 0.020 |
Why?
| | Necrosis | 1 | 2010 | 244 | 0.020 |
Why?
| | Diagnosis, Differential | 1 | 2013 | 1489 | 0.020 |
Why?
| | United States | 1 | 2024 | 15966 | 0.020 |
Why?
| | Time Factors | 1 | 2017 | 7173 | 0.020 |
Why?
| | Antiviral Agents | 1 | 2010 | 767 | 0.010 |
Why?
|
|
Dacey's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|